Screener
Royalty Pharma RPRX Litifilimab — Unfunded Commitments
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept rprx:ResearchAndDevelopmentUnfundedCommitments.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
| Product Candidates | Counterparties | Total Commitments | Funding Timing | Unfunded Commitments |
|---|---|---|---|---|
| JNJ‑4804 | Johnson & Johnson | $500,000 | Eight fixed quarterly payments commencing in the second quarter of 2026 | $437,500 |
| TEV-’408(1) | Teva Pharmaceuticals | 75,000 | Variable quarterly payments commencing in second quarter of 2026 | 65,149 |
| Litifilimab | Biogen | 250,000 | Six fixed quarterly payments commencing in first quarter of 2025 | — |
| Total | $825,000 | $502,649 |
Item 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Royalty Pharma's litifilimab — unfunded commitments?
- Royalty Pharma (RPRX) reported litifilimab — unfunded commitments of $0 in Q2 2026.
- What does litifilimab — unfunded commitments mean?
- This metric quantifies the remaining portion of the total contractual capital commitment that has not yet been disbursed to the development partner. It represents the future cash outflow required to satisfy the firm's obligations for the Litifilimab asset. Monitoring this helps investors forecast future liquidity requirements for specific pipeline assets.
Ask your AI about Royalty Pharma's litifilimab — unfunded commitments.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude